The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.
Source link
FDA Grants Priority Review to Enhertu for HER2-Low and -Ultralow Breast Cancer
The FDA has granted priority review to Enhertu for the potential treatment of HER2-low and HER2-ultralow breast cancer.The Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental biologics license application for Enhertu (trastuzumab deruxtecan) to treat patients with unresectable or metastatic HER2-low or -ultralow breast cancer treated with at least one endocrine therapy in the...
Read more
